Harrow to Acquire Melt Pharmaceuticals, Advancing Non-Opioid, Needle-Free Sedation Therapy MELT-300

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into an ag...

September 30, 2025 | Tuesday | News
Concept Life Sciences Expands Integrated Drug Discovery Facilities in High Peak

Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, announces the official openin...

September 30, 2025 | Tuesday | News
Sen-Jam and KVK Tech Complete NDA-Ready CMC Package and Submission Batches for SJP-002C

Completion of submission batches and NDA-ready CMC package strengthens regulatory foundation for upcoming Phase 2b/3 trials and underscores Sen-Jam's lea...

September 29, 2025 | Monday | News
ME Therapeutics Secures U.S. Patent for Lead G-CSF Antibody Candidate to Advance Cancer Immunotherapies

ME Therapeutics Holdings Inc. a publicly listed biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased ...

September 29, 2025 | Monday | News
Eisai and Biogen Gain Australian Approval for LEQEMBI® in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...

September 25, 2025 | Thursday | News
Santhera Secures CHF 20M in Growth Capital from Highbridge and R-Bridge

Santhera secures approximately CHF 20 million of additional funding from existing investors Highbridge and R-Bridge to accelerate global rollout Deman...

September 25, 2025 | Thursday | News
Ncardia Launches First iPSC-Derived Non-Human Primate Cardiomyocytes for Translational Cardiac Research

-Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment,  announced the launch of Ncyte® NHP-C vCardiomyo...

September 24, 2025 | Wednesday | News
Illumina Expands Global CDx Partnerships to Advance KRAS-Targeted Precision Oncology

Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the T...

September 24, 2025 | Wednesday | News
Angelini Pharma and South Korea’s Sovargen Sign Global Option Agreement for First-in-Class Brain Health Therapy SVG105

Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an...

September 23, 2025 | Tuesday | News
Esperion and Otsuka Secure MHLW Approval for NEXLETOL® in Japan to Treat Hypercholesterolemia

Esperion announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® ...

September 22, 2025 | Monday | News
Sanofi’s Brivekimig Demonstrates Positive Phase 2a Results in Moderate-to-Severe Hidradenitis Suppurativa

In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared...

September 18, 2025 | Thursday | News
Cenevo Launches Labguru Assistant to Bring AI-Driven Support Directly Into Scientists’ Daily Work

Cenevo is launching the Labguru Assistant, an AI-enabled extension to the Labguru solution designed to provide scientists with real-time, in-platform suppo...

September 18, 2025 | Thursday | News
Nxera and Cancer Research UK Dose First Patient in Phase 2a Trial of Novel Immunotherapy Drug HTL0039732 for Advanced Solid Tumors

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combinati...

September 17, 2025 | Wednesday | News
Belite Bio Completes Phase 3 DRAGON Trial of Tinlarebant in Stargardt Disease

Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S....

September 15, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close